What is the price of ImmunityBio (IBRX) today?

The current price of ImmunityBio (IBRX) is $ 7.70, representing a 211.74% gain over the past year. The stock began the year trading around $ 1.98 and is currently priced at $ 7.70. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does ImmunityBio (IBRX) pay dividends?

ImmunityBio (IBRX) did not pay dividends over the past year.

Is ImmunityBio (IBRX) a good investment?

ImmunityBio (IBRX) is currently trading at $ 7.70 with a P/E ratio of -21.02%. This represents a -910% premium compared to its historical average P/E. Over the past year, the stock has gained 211.74 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 211.74%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy ImmunityBio (IBRX) stock?

You can buy ImmunityBio (IBRX) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol IBRX and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of ImmunityBio (IBRX) yield today?

Over the past month, ImmunityBio (IBRX) has returned -12.70% — 211.74% over the past year, and -54.60% over the past five years, including price appreciation and dividends.In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.If you were to purchase 100 shares of ImmunityBio (IBRX) today at the current price of $ 7.70 your total investment would be $ 770.00.Based on historical performance, the investment would have grown to approximately:$ 2,400.40 after 1 year$ 349.58 after 5 years$ 770.00 after 10 yearsPast performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ImmunityBio (IBRX): Stock Price, Earnings & Key Metrics

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.88	7.40	33.81%	2.14%	$ 586.59 B	28.46%
PFE	20.06	1.67	8.35%	6.28%	$ 155.85 B	12.42%
ABBV	89.02	0.00	0.00%	3.12%	$ 376.19 B	6.91%
NVO	10.61	5.46	51.50%	4.98%	$ 166.18 B	33.05%
MRK	16.72	0.00	0.00%	2.70%	$ 305.21 B	28.08%
AZN	31.27	6.56	20.99%	1.55%	$ 319.77 B	17.41%
GILD	20.77	7.81	37.62%	2.24%	$ 176.72 B	28.90%
BMY	16.98	-3.52	-20.72%	4.23%	$ 119.74 B	14.64%
ZTS	19.59	15.72	80.25%	1.70%	$ 52.37 B	28.23%
REGN	17.51	2.52	14.41%	0.47%	$ 78.86 B	31.41%
HALO	24.94	161.91	649.21%	0.00%	$ 7.90 B	22.69%
AMGN	24.97	22.24	89.06%	2.70%	$ 192.51 B	20.98%
MCK	24.84	-1,089.08	-4,383.84%	0.36%	$ 107.82 B	1.09%
VRTX	28.42	6.02	21.18%	0.00%	$ 112.36 B	32.94%
CAH	30.78	-18.95	-61.56%	0.94%	$ 51.16 B	0.68%
HRMY	10.31	1.88	18.24%	0.00%	$ 1.64 B	18.27%
ADMA	16.29	5.01	30.78%	0.00%	$ 2.39 B	28.80%
BIIB	20.21	1.43	7.08%	0.00%	$ 26.12 B	13.07%

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. The company operates in the healthcare sector, specializing in therapies designed to activate and enhance the immune system’s ability to identify and destroy disease cells.

Its research strategy centers on combining different immune-modulating technologies to generate durable immune responses in complex diseases, particularly in oncology.

Core areas of development include:

Cancer immunotherapies targeting solid tumors
Therapeutic vaccine platforms based on viral vectors
Allogeneic cell therapies designed to activate immune responses
NK cell and T-cell activation technologies
Immunotherapy candidates for oncology and infectious diseases

ImmunityBio’s clinical programs primarily focus on conditions such as bladder cancer, metastatic tumors, and other solid cancers, with multiple therapies undergoing different stages of clinical development.

Industry dynamics affecting the company include regulatory approval processes, clinical trial outcomes, competition in oncology immunotherapy, research and development funding, and broader healthcare policy developments.

ImmunityBio, Inc. is listed on the Nasdaq under the ticker IBRX.

History and Development

ImmunityBio was founded in 2014 in California as a biotechnology company focused on developing immunotherapy platforms for cancer treatment.

Early research programs centered on designing therapies capable of stimulating stronger immune responses against cancer cells through combinations of vaccine-based technologies and immune cell activation strategies.

A key milestone occurred in 2021, when NantKwest merged with ImmunityBio, consolidating the companies’ immunotherapy research platforms and expanding the combined organization’s clinical development pipeline.

Since then, the company has continued advancing clinical programs in oncology and infectious disease treatments, while investing in research infrastructure and manufacturing capabilities designed to support the development of next-generation immunotherapies.

IBRX

ImmunityBio Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment IBRX

review the fundamentals of ImmunityBio shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT ImmunityBio

ImmunityBio Inc.

United States

12 years

-

History and Development

Additional Information

PROFIT X PRICE IBRX

Financial Results IBRX

IBRX cash flow

Asset, Revenue and Profit Growth - IBRX

IBRX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca